Water leak fixed with zip ties indicative of Dr. Reddy's sterile plant failings 

FDA Building 2
A 15-page, eight-observation Form 483 posted by the FDA shows multiple issues at Dr. Reddy's oncology drug plant that could result in contamination. (FDA)

When an FDA inspector raised questions about water streaming down some equipment in the fill-and-finish area at Dr. Reddy’s oncology plant in Duvvada, India, a quality control manager repeatedly waved it off as condensation.

When the inspector pointed out it was flowing from a tube that someone had tried to fix with three zip ties and was a problem in a sterile area, the manager finally acquiesced and stopped the filling line. 

That is only one example of the slipshod operations the FDA uncovered (PDF) during an August inspection that resulted in an eight-observation, 15-page Form 483 for the facility. It was the second citation in less than a year for the facility, a plant that has created ongoing quality concerns at the FDA over the potential for microbial contamination. 


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

RELATED: Dr. Reddy's Copaxone, NuvaRing generics derailed by FDA 

According to the highly redacted citation, the FDA also raised issues about the lack of validation for the sterilization processes as well as lack of visual verifications of cleanliness and other processes. The FDA was also worried that the air flow in the fill area was not being conducted in a way to keep particles from getting into the drugs. 

The company last month acknowledged the Form 483, but the FDA only posted it days ago. Dr. Reddy’s has said it planned to address the FDA’s concerns “comprehensively" within the timeline, but that has been an ongoing refrain from India’s second-largest drugmaker. 

RELATED: Another day, another Form 483 for a Dr. Reddy's plant

The oncology plant, which has previously been named in a warning letter, also received a Form 483 last October. But this plant is only one among a number of Dr. Reddy’s facilities where the FDA has found serious shortcomings. This was the fifth Dr. Reddy’s site this year to be given a Form 483 as the drugmaker struggles with quality and repeat violations. 

Dr. Reddy’s manufacturing issues also appear to be affecting the company’s ability to launch drugs. Although it did not explicitly say it was tied to manufacturing problems, the drugmaker last month received a Complete Response Letter for two potentially very lucrative products, generic versions of Teva’s Copaxone and Merck’s birth control device NuvaRing.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.